Fine, Kaplan and Black, R.P.C. announces that people who paid or were reimbursed for certain prescription generic drug costs in the United States during the period from May 1, 2009, to December 31, 2019 may be eligible to submit a claim for a settlement payment. The firm states that the notice is authorized by a federal court and that eligible individuals can file a class action settlement claim form through the settlement website listed in the notice. According to the announcement, the class action settlement has a total value of $533 million. The communication is presented as a legal notice rather than a solicitation, and it includes a phone number and website for information about submitting a claim.
The notice references the class action case “In re Generic Pharmaceuticals Antitrust Litigation,” indicating that the settlement is tied to antitrust allegations involving generic pharmaceuticals. The materials do not provide additional details about specific drugs or reimbursement mechanisms beyond the time window and the requirement that claimants paid or had eligible costs reimbursed in the U.S.
